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OHIO ASSOCIATION OF BLOOD BANKS 
PROFICIENCY SAMPLE: 
RESULTS FOR A D sup(u) SPECIMEN 
Judy Duckett, Mary L. Morrison 
Introduction 
The Scientific and Education Committee of the Ohio 
Association of Blood Banks (OABB) recently sent a D sup(u) 
specimen to 110 institutions in the state as one of its 
proficiency samples. This particular sample was se- 
lected to survey the current standard of practice in 
Ohio for determining Rh immune globulin candidacy. 
Although there was some disagreement concerning 
RhIg candidacy because a prenatal blood type was un- 
available, the most significant result was that out of the 
87 responses received, the Rh type was reported 25 
different ways. 
Selected comments: 
Patient has already formed antibody 
Patient is true D sup(u)-pos 
Prenatal typing showed patient to be D sup(u)-pos 
D sup(u)-pos due to trans r sup(1) gene 
When test for either D or D sup(u) is positive, the 
label shall read Rh-pos; only Rh-neg women 
should receive Rh immune globulin 
Selected comments: 
If the patient is true D sup(u)-pos 
If there is a large fetal-maternal bleed 
Four vials if prenatal was D sup(u)-neg 
One vial-could be fetal cells 
Number of vials depends on fetal stain 
Patient is D-neg, D sup(u)-neg 
Comment: 




Conclusions Serological Procedures 
Procedures The April 1987 OABB proficiency specimen was 
A s  can be seen from the above results, there are nu- 
merous ways of reporting the D sup(u) phenotype. Although 
the majority of responses listed the Rh type as D-neg, 
D sup(u)-pos, a review of the current literature indicates that 
this is no longer considered acceptable terminology. 
UAT 19 Routine Negative In 1982, Konugres et al sup(1) used the term “Rh-positive, 
(or autocontrol) To validate D sup(u) D sup(u) - variant” to describe the three known mechanisms 
Responses Reason performed Result performed group O, D sup(u)-positive. 
ABO 80 Routine–or to Group O 
complete 
question #1 (see 
below) 
Rh type 87 Routine See Question #1 
D sup(u) 87 Routine Positive 85 
Mixed field 2 
of weak expression of the D antigen. That article ap- 
pears to have instigated the latest controversy over 
proper Rh terminology. Lacey et al, sup(2) Broman, sup(3) Moore, sup(4) 
To check for other 
antibodies 
Rosetting test 16 Routine for OB pts Positive 11 
Invalid 5 To screen for Ph-pos 
fetal cells and Issit sup(5) all agree that the term D sup(u)-variant should be 
Fetal hemoglobin 33 To determine if there Negative 25 used only when it has been determined that the D sup(u) phe- 
notype represents a lack of a portion of the D mosaic. 
Broman. sup(3) Isitt. sup(5) and Widmadmann sup(6) agree that “D - D sup(u) + ” 
was a large fetal- Positive 2 
maternal bleed and if so, Sent Out 6 
the number of vials of (results 
stain 
Rh immune globulin unknown) 
needed 
To rule out anti-U 
Antibody scrceen 55 Routine Negative 
C-typing 7 Because of D sup(u)-pos Positive 
Rh phenotype 4 Because of U sup(u)-pos C+,E-,c+ 
e +  
Answers to Questions 
1. What is the patient’s blood type? 
All respondents agreed that the patient was group 
O. Her Rh type was reported 25 different ways. 
The Rh type results were consolidated into the 
following six results. 
O pos 9 
0 pos (D sup(u)-pos) 5 
O pos, D sup(u)-variant 17 
0 D sup(u)-pos 13 
O D-neg, D sup(u)-pos 41 
O neg, D sup(u)-neg 2 
2. According to your institution’s policy, is the patient 
a candidate for Rh immune globulin? Why? 
NO-70 
Y 
should no longer he used. However, they do not agree 
on the terminology that should be used in its place. 
Widmadmann sup(6) prefers to use the term “O (or other ABO 
group) positive, Dsup(u)-variant” or “O pos, D sup(u) pos”; 
Broman sup(3) suggests using either “D” or Rh + D sup(u),” while 
Issitt sup(5) suggests that these cells should be called “D sup(u).” 
Zuck sup(7) also suggests that “D sup(u) phenotype” may be the 
appropriate generic term to use. 
The controversy continues when the question of 
whether D sup(u) women who give birth to D-positive chil- 
dren are candidates for Rh immune globulin. Many in- 
vestigators feel that, because the vast majority of D sup(u) in- 
dividuals possess all portions of the D mosaic and are 
unable to form anti-D, routine Rh immune globulin 
prophylaxis for D sup(u) women is not justified. sup(8,9) Others, 
however, feel that the D-mosaic women should be pro- 
tected.” Ultimately, the use of Rh immune globulin for 
D sup(u) women is a decision, at this point in time, that must 
be made by the patient’s physician. 
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THE IMMUNOHEMATOLOGY 
CONSULTATION REPORT 
WHAT, WHEN, HOW MUCH? 
Kathryn M. Beattie 
Introduction 
There is no doubt about the mandate to maintain 
blood bank records and reports. The Code of Federal 
Regulations (CFR 606.160) states: 
Records shall be maintained that include, but 
(b) (4) Compatibility test records: 
are not limited to the following: 
(i) Results of all compatibility tests, 
including crossmatching, testing of 
patient samples, antibody screening 
and identification. 
(ii) Results of confirmatory testing. 
(6)  Transfusion reaction reports and com- 
plaints, including records of investiga- 
tions and follow-up. 
The American Red Cross (ARC) Blood Service Direc- 
tive 6.5 explains in detail how ARC reference labora- 
tories must comply with the Federal Regulations for 
records. It states: 
Each patient specimen studied must have the 
A. Antibody identification including special 
following records: 
cell typing and a report to the submitting 
hospital. 
B. Units screened and found compatible. 
C. All special typings or procedures 
performed. 
It also says these records must be kept indefinitely. 
Immunohematology Reference Laboratory 
Reports 
What information should be included in a reference 
laboratory report? The closest direction about content 
can be found in the ARC Good Manufacturing Prac- 
tices (GMP) Inspection Checklist which asks: "Do 
patient consultation report forms include name and 
address of Red Cross Center, patient name and identifi- 
cation numbers, date, serologic data, transfusion rec- 
ommendations or clinical significance of antibody, 
referral laboratory, and name of person sending 
report?" 
Identification 
What is the need for patient identification? There is 
no doubt that the name and address of the submitting 
and reference laboratories and the name of the patient 
must appear in the report. The submitting hospital's 
identification number for the patient should appear so 
that the report will be placed in the correct chart. As 
patients are now rapidly discharged, the reference lab- 
oratory report may not arrive at the submitting hos- 
pital until after the patient is discharged, which means 
that the correct chart will have to be found in the med- 
ical records files. 
Many patients have similar or identical first and last 
names and hospital admission codes can change with 
each admission. Therefore, social security numbers 
and birthdates would allow better identification of the 
patient by the referral reference laboratory when the 
patient is subsequently admitted, perhaps at another 
hospital, and further work is requested. 
Turnaround time 
Three dates-the date of specimen collection, the 
date of receipt by the referral laboratory, and the date 
the report is sent-should appear in the report. The 
first two dates aid in establishing the chronology of 
events if a series of specimens is sent and an evolving 
picture develops, such as the detection of new anti- 
bodies, interim transfusions, transfusion reaction 
investigations, etc. 
The third date—the date the report is sent- 
provides a means of documenting the turnaround 
time. Turnaround time can be affected by a number of 
factors, including volume and complexity of cases, 
number of reference personnel available, overtime 
availability, etc. Knowledge of turnaround time allows 
laboratory personnel to examine the system and to 
pinpoint areas that need attention. 
Many reference laboratories telephone the report to 
the submitting laboratory as soon as  the work is com- 
pleted. If blood is needed, information concerning 
availability of compatible units and crossmatching 
techniques need not await a written report. If speci- 
ficity of the antibody or antibodies has not been deter- 
mined by the end of a normal work day, the urgency of 
the patient's need for blood can be ascertained, and 
from this telephone consultation a decision can be 
made concerning the need for overtime. 
If there is no urgent need for blood and the case re- 
quires more extensive or complex testing, a prelimi- 
